Objective: This study was designed to assess the apolipoprotein B (Apo–B), apolipoprotein A (Apo A) and Apo B/Apo A–I ratio in subjects with and without metabolic syndrome and to evaluate the correlation of Apo B/Apo A–I ratio with oxidative stress marker and cardiovascular disease risk. Methods: A total of 308 subjects including one hundred and fifty– five cases and one hundred and fifty– three controls were recruited for this study. All the subjects were classified according to the NCEP ATP III (National cholesterol education program – Adult treatment panel III) criteria for MetS. Anthropometric and clinical characteristics were recorded using clinical Proforma. Blood samples were collected for doing plasma glucose, Lipid profile analysis [Total Cholesterol (TC), Triglyceride (TG), high–density lipoprotein (HDL)], ApoA1, Apo B and oxidative stress marker – Malondialdehyde (MDA). Serum low–density lipoprotein (LDL), very–low–density lipoprotein (VLDL) and Apo B/Apo A–I ratio were calculated. Comparison of data between the two groups was done by t test. Correlation coefficient of Apo B/ Apo A1 ratio with cadiometabolic risk factors were calculated. Result: We found that cardiometabolic risk factors like abdominal obesity, systolic and diastolic blood pressure, fasting plasma glucose, TG, atherogenic lipoproteins LDL, Apo B, Apo B/Apo A–I ratio and MDA were significantly high in subjects with MetS whereas anti–atherogenic factor Apo A1 was significantly low. We also observed that Apo B/AI ratio was positively related to cardiometabolic risk factors and with oxidative stress marker. Conclusion: Apo B/AI ratio was related to metabolic syndrome and was found to be a reliable indicator of cardiovascular risk in MetS.